問卷

TPIDB > Search Result > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Radiation Therapy

Division of Radiology

Division of Cardiovascular Diseases

Kaohsiung Veterans General Hosptial (在職)

Division of Radiology

Division of Urology

更新時間:2023-09-19

王俊傑Wang, Chun-Chieh
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 9 個月
  • jjwang@cgmh.org.tw

篩選

List

22Cases

2019-03-01 - 2026-12-31

Phase II

Active
A Phase II, Randomized, Open-Label, Parallel-Group Autologous Dendritic Cell Vaccination as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients
  • Condition/Disease

    Glioblastoma Multiforme (GBM)

  • Test Drug

    ADCV01

Participate Sites
4Sites

Recruiting3Sites

Terminated1Sites

2011-07-01 - 2012-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2021-03-31 - 2027-06-30

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
15Sites

Terminated15Sites

2011-08-01 - 2014-07-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2017-11-01 - 2022-12-31

Phase I/II

A Dose Escalation, Expansion Study of Vofatamab (B-701) Alone, Plus Docetaxel, or Versus Docetaxel in Subjects with Locally Advanced or Metastatic Urothelial Cell Carcinoma who have Relapsed After, or are Refractory to Standard Therapy.
  • Condition/Disease

    Locally Advanced or Metastatic Urothelial Cell Carcinoma

  • Test Drug

    Vofatamab (B-701)

Participate Sites
9Sites

Terminated8Sites

蘇柏榮
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2010-08-30 - 2012-11-30

Phase III

A Phase III, Prospective, Randomized, Double-Blind, PlaceboControlled Multicenter Study to Evaluate the Efficacy and Safety of MK-6621 in Patients with Atrial Fibrillation
  • Condition/Disease

    Atrial Fibrillation

  • Test Drug

    MK-6621

Participate Sites
16Sites

Terminated16Sites

2020-08-01 - 2025-04-07

Phase III

A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer
  • Condition/Disease

    Metastatic Castration-Resistant Prostate Cancer

  • Test Drug

    Cabometyx; Tecentriq; Zytiga; Xtandi; Prednisone

Participate Sites
8Sites

Recruiting4Sites

Terminated4Sites

2023-12-01 - 2026-04-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2023-11-01 - 2026-07-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

1 2 3